Insider Trading activities at Apex Bioventures Acquisition Corp (PEX)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apex Bioventures Acquisition Corp (PEX) since 2008 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Apex Bioventures Acquisition Corp. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 1368613.

Total stock buying since 2008: $736,000.
Total stock sales since 2008: $4,413,415.
Total stock option exercises since 2008: $0.

▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies


Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Apex Bioventures Acquisition Corp (PEX).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2009 0 $0 189,500 $1,472,415 0 $0
2008 100,000 $736,000 400,000 $2,941,000 0 $0

Table 2. Monthly summary of insider trading at Apex Bioventures Acquisition Corp (PEX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2009-04 0 $0 189,500 $1,472,415 0 $0
2008-12 0 $0 100,000 $736,000 0 $0
2008-04 100,000 $736,000 300,000 $2,205,000 0 $0

Table 3. Detailed insider trading at Apex Bioventures Acquisition Corp (PEX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2009-04-22 Deutsche Bank Ag\ (10% Owner) Sale 189,500 7.77 1,472,415
2008-12-16 Deutsche Bank Ag\ (10% Owner) Sale 100,000 7.36 736,000
2008-04-18 Deutsche Bank Ag\ (10% Owner) Sale 200,000 7.35 1,470,000
2008-04-17 Deutsche Bank Ag\ (10% Owner) Buy 100,000 7.36 736,000

Insider trading activities including stock purchases, stock sales, and option exercises of PEX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Apex Bioventures Acquisition Corp (symbol PEX, CIK number 1368613) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.